Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 24 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $798.42, which forecasts a -1.71% decrease in the stock price over the next year. The lowest target is $587 and the highest is $1,057.

Price Target: $798.42 (-1.71%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$587	$798.42	$800	$1,057
Change	-27.73%	-1.71%	-1.51%	+30.13%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	6	6	6	8	8	9
Buy	10	10	9	8	7	7
Hold	6	6	5	6	7	7
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	23	23	21	23	23	24

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tazeen Ahmad B of A Securities	B of A Securities	Sell → Strong Buy Upgrades $627 → $860	Sell → Strong Buy	Upgrades	$627 → $860	+5.88%	Jan 7, 2026
Matthew Harrison Morgan Stanley	Morgan Stanley	Hold Maintains $767 → $768	Hold	Maintains	$767 → $768	-5.45%	Dec 12, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Hold Maintains $700 → $745	Hold	Maintains	$700 → $745	-8.28%	Dec 10, 2025
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $850 → $1,057	Strong Buy	Maintains	$850 → $1,057	+30.13%	Dec 4, 2025
Evan David Seigerman BMO Capital	BMO Capital	Buy Maintains $725 → $850	Buy	Maintains	$725 → $850	+4.65%	Dec 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.48B

Increased by 1.99%

from 14.20B

Revenue Next Year

15.45B

Increased by 6.68%

from 14.48B

EPS This Year

43.90

Increased by 14.51%

from 38.34

EPS Next Year

46.06

Increased by 4.92%

from 43.90

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	8.50B	16.07B	12.17B	13.12B	14.20B	14.48B	15.45B
Revenue Growth	29.58%	89.14%	-24.26%	7.76%	8.27%	1.99%	6.68%
EPS	30.52	71.97	38.22	34.77	38.34	43.90	46.06
EPS Growth	65.33%	135.81%	-46.90%	-9.03%	10.27%	14.51%	4.92%
Forward PE	-	-	-	-	-	18.50	17.63
No. Analysts	-	-	-	-	-	31	29

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	15.3B	17.5B
Avg	14.5B	15.5B
Low	13.6B	13.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	7.7%	21.1%
Avg	2.0%	6.7%
Low	-4.4%	-6.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	48.14	55.93
Avg	43.90	46.06
Low	38.57	39.99

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	25.6%	27.4%
Avg	14.5%	4.9%
Low	0.6%	-8.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.